Abstracts tagged "Biomarkers"

Abstract Number: 558 • 2016 ACR/ARHP Annual Meeting
Clinical, Sonographic and Immunological Biomarkers of Ramris Progression in RA Patients in Clinical Remission: A Prospective Study with 12 Months of Follow-up
Julio Ramírez¹, Andrea Cuervo², Jose Antonio Narváez³, Virginia Ruiz-Esquide², Javier Hernández-Gañán³, Raquel Celis⁴, Jose Inciarte-Mundo², M. Victoria Hernández², Jose L. Pablos⁵, Raimon Sanmarti² and Juan D. Cañete², ¹Rheumatology, Hospital Clínic, Barcelona, Spain, ²Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ³Radiology, Hospital Bellvitge, Barcelona, Spain, ⁴Rheumatology, Arthritis Unit, Barcelona, Spain, ⁵Grupo de Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain
Background/Purpose: To determine clinical, sonographic and immunological biomarkers predicting structural damage progression at 12 months of follow-up as measured by Magnetic Resonance Imaging (MRI) in a…
Abstract Number: 1046 • 2016 ACR/ARHP Annual Meeting
Anti-TNF Therapy in Axial Spondyloarthritis: Prediction of Therapeutic Responses Using Immunological Signatures
Lars Rogge¹, Silvia Menegatti², Eleonora Latis¹, Elena Mascia¹, Hanane Yahia¹, Claire Leloup¹, Anna Molto³, Corinne Miceli-Richard⁴, Maxime Dougados^5,6 and Elisabetta Bianchi¹, ¹Immunology, Institut Pasteur, Paris, France, ²Immunology, Immunoregulation Unit, Institut Pasteur, Paris, France, ³Hopital Cochin, Paris Descartes University, Paris, France, ⁴Rheumatology, Hôpital Cochin, Paris, France, ⁵Paris Descartes University, Paris, France, ⁶Service de Rhumatologie B, Hopital Cochin, Paris, France
Background/Purpose: The introduction of anti-TNF therapy has proven effective to reduce inflammation and clinical symptoms in several chronic inflammatory diseases. However, TNF-blockers are effective only…
Abstract Number: 1677 • 2016 ACR/ARHP Annual Meeting
Serum Complement C3 Component As a Potential Disease Activity Marker in Psoriatic Arthritis
Andreas Kerschbaumer^1,2, Karl Fenzl², Michael Weber³, Johannes Resch⁴, Martin Kasper⁴, Daniel Aletaha⁵ and Ludwig Erlacher^4,6, ¹Department of Internal Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ²Institute for Autoimmune Diseases and Rheumatology, Karl Landsteiner Institute, Vienna, Austria, ³Medical University of Vienna, Vienna, Austria, ⁴2nd Medical Department, Department for Rheumatology, Osteology and Geriatric medicine, Sozialmedizinisches Zentrum Sued, Vienna, Austria, ⁵Department of Internal Medicine 3, Medical University of Vienna, Vienna, Austria, ⁶Karl Landsteiner Institute, Vienna, Austria
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis that occurs in a subgroup of patients suffering from psoriasis. Assessment of PsA disease activity currently mainly…
Abstract Number: 2423 • 2016 ACR/ARHP Annual Meeting
Differential Interferon Score Expression in the Peripheral Blood in Mendelian Inflammatory Interferonopathies Versus Juvenile Dermatomyositis (JDM) Subtyped By Myositis Autoantibodies and Disease Activity
Hanna Kim¹, Terrance P. O'Hanlon², Adriana Almeida de Jesus³, Yan Huang³, Ira N. Targoff^4,5, Frederick W. Miller², Raphaela Goldbach-Mansky⁶ and Lisa G. Rider², ¹NIAMS/NIH, Bethesda, MD, ²Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ³National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵University of Oklahoma, Oklahoma City, OK, ⁶Translational Autoinflammatory Disease Studies, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD
Background/Purpose: JDM is a complex autoimmune disease with an interferon (IFN) signature, with a reported correlation with disease activity. Clinical features vary among myositis-specific autoantibody…
Abstract Number: 2647 • 2016 ACR/ARHP Annual Meeting
Drug Trough Serum Levels Rather Than Antidrug Antibodies Explain Disease Flares in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with TNF Inhibitors in Clinical Remission/Low Disease Activity: A One Year Prospective, Multicenter Study (INMUNOREMAR)
Raimon Sanmarti¹, Jose Inciarte-Mundo¹, Paula Estrada², Maria García Manrique³, Javier Narváez⁴, Antonio Gomez-Centeno³, Jesús Rodríguez-Moreno⁴, Mariona Pascal⁵ and Jordi Yagüe⁵, ¹Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ²Rheumatology Department, Hospital Moisès Broggi-Hospital General de L'Hospitalet - Consorci Sanitari Integral, Sant Joan Despí, Spain, ³Rheumatology Department, Hospital Parc Taulí, Sabadell, Spain, ⁴Rheumatology Department, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Spain, ⁵Immunology Department, Hospital Clinic de Barcelona, Barcelona, Spain
Background/Purpose: To determine predictive factors of disease flares, including drug trough serum levels and anti-drug antibodies (Ab) in patients with rheumatoid arthritis (RA) or polyarticular…
Abstract Number: 3217 • 2016 ACR/ARHP Annual Meeting
Broad-Based Interrogation of the Serum Proteome Suggests That RA Onset Is Associated with Activation of the Intrinsic Coagulation Cascade
Liam O'Neil¹, Xiaobo Meng², Irene Smolik³, Carol Hitchon² and Hani El-Gabalawy⁴, ¹Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ²University of Manitoba, Winnipeg, MB, Canada, ³Arthritis Center, University of Manitoba, Winnipeg, MB, Canada, ⁴University of Manitoba Arthritis Center, Winnipeg, MB, Canada
Background/Purpose: The establishment of longitudinal pre-clinical RA cohorts is beginning to provide important insights into the mechanisms that precede the onset of clinically detectable disease.…
Abstract Number: 13 • 2016 ACR/ARHP Annual Meeting
Genetic Variants of the Vasoactive Intestinal Peptide (VIP) Gen in Association with Rheumatoid Arthritis Treatment Requirements
Iria V. Seoane¹, Carmen Martinez², Yasmina Juarranz¹, Rosario García-Vicuña³, Eva Tomero⁴, Rosa P Gomariz¹, Isidoro Gonzalez-Alvaro³ and Amalia Lamana⁵, ¹Cellular Biology, School of Biology. Universidad Complutense de Madrid, Madrid, Spain, ²Cellular Biology, School of Medicine. Universidad Complutense de Madrid, Madrid, Spain, ³Rheumatology, Rheumatology Service, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ⁴Rheumatology, Hospital Universitario de la Princesa, Madrid, Spain, ⁵Rheumatology, Hospital Universitario de La Princesa. IIS Princesa, Madrid, Spain
Background/Purpose: Biomarkers to recognize patients with a more intensive therapy necessity in rheumatoid arthritis are essential and scarce. VIP has shown immunoregulatory properties both in…
Abstract Number: 577 • 2016 ACR/ARHP Annual Meeting
TCZ Modulates the Production of Ccfdna Derived from RA Synovial Cells
Naonori Hashimoto¹, Kohsuke Yoshida¹, Teppei Hashimoto², Ayako Nakai¹, Kenta Kaneshiro¹, Kohjin Suzuki¹, Yoshiko Kawasaki², Nao Shibanuma³, Natsuko Nakagawa⁴, Yoshitada Sakai⁵ and Akira Hashiramoto⁶, ¹Department of Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Japan, ²Department of Rheumatology, Kobe Kaisei Hospital, Kobe, Japan, ³Departmant of Orthopaedic Surgery, Kobe Kaisei Hospital, Kobe, Japan, ⁴Department of Orthopaedic Surgery, Konan-Kakogawa Hospital, Kakogawa, Japan, ⁵Division of Rehabilitation Medicine, Kobe University Graduate School of Medicine, Kobe, Japan, ⁶Department of Biophysics, Department of Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Japan
Background/Purpose: DNA is fragmented and released into blood circulation as a circulating cell-free DNA (ccfDNA) because of damage or death of cells. Although the…
Abstract Number: 1106 • 2016 ACR/ARHP Annual Meeting
Test of the Spleen Tyrosine Kinase Inhibitor Fostamatinib in a Translational Joint Tissue Model Show Significant Effect on Bone, but Not on Synovial Tissue
Cecilie F. Kjelgaard-Petersen^1,2, Anne C. Bay-Jensen³, Thorbjørn G. Christiansen⁴, Morten Asser Karsdal³, Per Hägglund² and Christian S. Thudium¹, ¹Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ²Systems Biology, Technical University of Denmark, Kgs. Lyngby, Denmark, ³Rheumatology, Nordic Bioscience, Herlev, Denmark, ⁴Gentofte University Hospital, Orthopaedicsurgery unit, Gentofte, Denmark
Background/Purpose: The Spleen tyrosine kinase (Syk) inhibitor fostamatinib was not approved as treatment for rheumatoid arthritis (RA) due to insufficient effect on joint structure in…
Abstract Number: 1695 • 2016 ACR/ARHP Annual Meeting
Pharmacological Monitoring of Adalimumab and Etanercept-Treated Psoriatic Arthritis Patients in Predicting Future Treatment Response
Meghna Jani¹, Hector Chinoy², Anne Barton² and on behalf of OUTPASS, ¹Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, ²Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom
Background/Purpose: Up to 40% of patients with inflammatory arthritis on TNF-α inhibitor (TNFi) treatment fail to respond either due to primary inefficacy or loss of…
Abstract Number: 2425 • 2016 ACR/ARHP Annual Meeting
The Vasculopathy of Juvenile Dermatomyositis (JDM); Evidence of Persistent Endothelial Injury, Hypercoagulability, Subclinical Inflammation and Increased Arterial Stiffness
Charalampia Papadopoulou^1,2, Ying Hong¹, Petra Krol^1,2, Yiannis Ioannou³, Clarissa Pilkington^2,4,5, Hema Chaplin⁶, Stephanie Simou¹, Marietta Charakida⁷, Lucy R Wedderburn^5,8,9, Paul Brogan¹⁰ and Despina Eleftheriou^1,8,11, ¹Infection, Inflammation and Rheumatology, UCL Institute of Child Health, London, United Kingdom, ²Paediatric Rheumatology, Great Ormond Street Hospital NHS Trust, London, United Kingdom, ³Rayne Institute, Arthritis Research UK Centre for Adolescent Rheumatology, UCL Division of Medicine, London, United Kingdom, ⁴Paediatric Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ⁵Infection, Inflammation and Rheumatology Section, UCL Institute of Child Health, London, United Kingdom, ⁶Centre for Adolescent Rheumatology, Arthritis Research UK, London, United Kingdom, ⁷Vascular Physiology Unit, Institute of Cardiovascular Science , University College London, London, United Kingdom, ⁸Paediatric Rheumatology Department, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ⁹Rheumatology Unit, Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ¹⁰Department of Paediatric Rheumatology, UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ¹¹Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom
Background/Purpose: Vasculopathy is considered central to the pathogenesis of Juvenile Dermatomyositis (JDM). The interplay between persistent JDM-vasculopathy, traditional cardiovascular risk factors, exposure to corticosteroids, and…
Abstract Number: 2823 • 2016 ACR/ARHP Annual Meeting
Urinary Angiostatin, CXCL4 and VCAM-1 As Biomarkers for Lupus Nephritis
Chi Chiu Mok¹, Samar Soliman², Ling Yin Ho³ and Chandra Mohan², ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Biomedical Engineering, University of Houston, Houston, TX, ³Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong
Background/Purpose: Proteomic screening is an efficient approach for identifying protein biomarkers in various inflammatory diseases. Our preliminary proteomic analysis revealed elevated levels of urinary angiostatin,…
Abstract Number: 3218 • 2016 ACR/ARHP Annual Meeting
Synovial Mast Cells Associate with High Disease Activity and Predict Radiographic Progression at 12 Months in Patients with Early Rheumatoid Arthritis
Felice Rivellese¹, Frances Humby¹, Stephen Kelly¹, Amato de Paulis², Gianni Marone² and Costantino Pitzalis¹, ¹Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ²Department of Translational Medical Sciences and Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Naples, Italy
Background/Purpose: Mast cells (MCs) are immune cells present in the synovial membrane and implicated in the pathogenesis of Rheumatoid Arthritis, although their exact contribution…
Abstract Number: 28 • 2016 ACR/ARHP Annual Meeting
Baseline Serum Inflammatory Biomarkers at Cohort Entry in 1974 Predicted Cardiovascular Disease (CVD) Mortality from 1995 through 2015 in a Prospective, Community-Based Study of Incident Rheumatoid Arthritis (RA) Patients and Matched Non-RA (CN) Subjects
Alfonse T. Masi¹, Azeem A. Rehman², Laura Jorgenson³ and Jean C. Aldag³, ¹University of Illinois, College of Medicine at Peoria, Peoria, IL, ²Neurosurgery, University of West Virginia Medical School, Morgantown, WV, ³Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL
Baseline Serum Inflammatory Biomarkers at Cohort Entry in 1974 Predicted Cardiovascular Disease (CVD) Mortality from 1995 through 2015 in a Prospective, Community-Based Study of Incident Rheumatoid…
Abstract Number: 587 • 2016 ACR/ARHP Annual Meeting
Synovial Immunophenotype and Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis Patients: Relationship to Treatment Response and Radiological Prognosis
Carl Orr¹, Aurélie Najm², Monika Biniecka³, Francis Young¹, Ursula Fearon⁴ and Douglas J. Veale¹, ¹Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin 4, Ireland, ²Rheumatology, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin, Ireland, ³St. Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin, Ireland, ⁴Trinity College Dublin, Department of Molecular Rheumatology, Trinity College Dublin, Dublin, Ireland
Background/Purpose: Circulating anti-citrullinated peptide antibodies (ACPA) have been proposed as an important clinical test for stratification of patients presenting with rheumatoid arthritis (RA). ACPA may…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].